evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,811 questions · 70,850 findings · 5,139 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 15,174 · 21.4%GRADE not reported 6,479 · 9.1%Very low 17,330 · 24.5%Low 17,814 · 25.1%Moderate 11,056 · 15.6%High 2,997 · 4.2%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to 8‐weekly (every other month) vs sham

Safety: Development of macular neovascularisation or exudative AMD at 1 year · adults with GA due to AMD

Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to… showed no clear difference in safety: Development of macular neovascularisation or exudative AMD… compared with sham (low certainty).

1 finding from 1 review

Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to 8‐weekly (every other month) vs sham

Safety: Development of endophthalmitis at 1 year · adults with GA due to AMD

Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to… showed no clear difference in safety: Development of endophthalmitis at 1 year compared with sham (moderate certainty).

1 finding from 1 review

Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to 8‐weekly (every other month) vs sham

Loss of ≥ 15 letters BCVA at 1 year · adults with GA due to AMD

Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to… showed no clear difference in loss of ≥ 15 letters BCVA at 1 year compared with sham (moderate certainty).

1 finding from 1 review

Summary of findings 3: Efficacy and safety of IVT pegcetacoplan 4‐weekly (monthly) vs sham

Safety: Development of macular neovascularisation or exudative AMD at 1 year · adults with GA due to AMD

Summary of findings 3: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in safety: Development of macular neovascularisation or exudative AMD… compared with sham; GRADE not reported.

1 finding from 1 review

Summary of findings 3: Efficacy and safety of IVT pegcetacoplan 4‐weekly (monthly) vs sham

Safety: Development of endophthalmitis at 1 year · adults with GA due to AMD

Summary of findings 3: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in safety: Development of endophthalmitis at 1 year compared with sham (moderate certainty).

1 finding from 1 review

Summary of findings 4: Efficacy and safety of IVT pegcetacoplan 8‐weekly (every other month) vs sham

Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with GA due to AMD

Summary of findings 4: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in change in BCVA from baseline at 1 year (ETDRS letters) compared with sham (moderate certainty).

1 finding from 1 review

Summary of findings 4: Efficacy and safety of IVT pegcetacoplan 8‐weekly (every other month) vs sham

Safety: Development of macular neovascularisation or exudative AMD at 1 year · adults with GA due to AMD

Summary of findings 4: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in safety: Development of macular neovascularisation or exudative AMD… compared with sham; GRADE not reported.

1 finding from 1 review

Summary of findings 4: Efficacy and safety of IVT pegcetacoplan 8‐weekly (every other month) vs sham

Safety: Development of endophthalmitis at 1 year · adults with GA due to AMD

Summary of findings 4: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in safety: Development of endophthalmitis at 1 year compared with sham (moderate certainty).

1 finding from 1 review